| A phase 3 trial of bevacizumab in ovarian cancer TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ... New England Journal of Medicine 365 (26), 2484-2496, 2011 | 2529 | 2011 |
| Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer K Moore, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, ... New England Journal of Medicine 379 (26), 2495-2505, 2018 | 2376 | 2018 |
| Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... New England Journal of Medicine 366 (15), 1382-1392, 2012 | 2092 | 2012 |
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised … J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 15 (8), 852-861, 2014 | 1713 | 2014 |
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised … J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 15 (8), 852-861, 2014 | 1710 | 2014 |
| Epithelial ovarian cancer S Lheureux, C Gourley, I Vergote, AM Oza The Lancet 393 (10177), 1240-1253, 2019 | 1344 | 2019 |
| Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria, RC Bast Jr, V Beral, ... Nature reviews Cancer 15 (11), 668-679, 2015 | 1133 | 2015 |
| Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval PC Fong, TA Yap, DS Boss, CP Carden, M Mergui-Roelvink, C Gourley, ... Journal of clinical oncology 28 (15), 2512-2519, 2010 | 1108 | 2010 |
| Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer KL Bolton, G Chenevix-Trench, C Goh, S Sadetzki, SJ Ramus, BY Karlan, ... Jama 307 (4), 382-389, 2012 | 731 | 2012 |
| Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin … SB Kaye, J Lubinski, U Matulonis, JE Ang, C Gourley, BY Karlan, ... J Clin Oncol 30 (4), 372-379, 2012 | 587 | 2012 |
| Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo … JA Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 17 (11), 1579-1589, 2016 | 489 | 2016 |
| How do chemotherapeutic agents damage the ovary? S Morgan, RA Anderson, C Gourley, WH Wallace, N Spears Human reproduction update 18 (5), 525-535, 2012 | 459 | 2012 |
| Copy number signatures and mutational processes in ovarian carcinoma G Macintyre, TE Goranova, D De Silva, D Ennis, AM Piskorz, M Eldridge, ... Nature genetics 50 (9), 1262-1270, 2018 | 380 | 2018 |
| Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression MA Dozynkiewicz, NB Jamieson, I MacPherson, J Grindlay, ... Developmental cell 22 (1), 131-145, 2012 | 357 | 2012 |
| Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial M Sharpe, J Walker, CH Hansen, P Martin, S Symeonides, C Gourley, ... The Lancet 384 (9948), 1099-1108, 2014 | 276 | 2014 |
| Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo … S Banerjee, KN Moore, N Colombo, G Scambia, BG Kim, A Oaknin, ... The Lancet Oncology 22 (12), 1721-1731, 2021 | 238 | 2021 |
| Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor–positive patients JF Smyth, C Gourley, G Walker, MJ MacKean, A Stevenson, ... Clinical Cancer Research 13 (12), 3617-3622, 2007 | 237 | 2007 |
| The BRCA1-Δ11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin Y Wang, AJ Bernhardy, C Cruz, JJ Krais, J Nacson, E Nicolas, S Peri, ... Cancer research 76 (9), 2778-2790, 2016 | 232 | 2016 |
| Solid dose delivery vehicle and methods of making same BJ Roser, J Kampinga, C Colaco, J Blair US Patent 6,811,792, 2004 | 210 | 2004 |
| Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes DR Hodgson, BA Dougherty, Z Lai, A Fielding, L Grinsted, S Spencer, ... British journal of cancer 119 (11), 1401-1409, 2018 | 205 | 2018 |
